Use of Ovine Polyclonal Antibodies to Treat Severe Clostridium difficile Infections

Sheep are being turned into living factories for antibodies that can neutralise the toxins released by *Clostridium difficile*, a bacterium that causes severe, sometimes fatal, hospital-acquired diarrhoea. This matters because *C. difficile* infections now outnumber MRSA cases in hospitals, and the US Centers for Disease Control and Prevention reports that deaths from this single pathogen exceed those from all other intestinal diseases combined. Standard antibiotics kill the bacteria but do nothing about the two powerful toxins they release, which continue to damage the gut lining even after the infection is cleared. The project uses a method similar to infant vaccination: sheep are immunised with tiny, inactivated amounts of the toxins. Their immune systems produce specific antibodies, which are then purified from the blood and packaged into injectable doses. Given intravenously alongside antibiotics, these antibodies bind directly to the toxins and neutralise them. If successful, this approach could provide a targeted, fast-acting treatment for patients with severe *C. difficile* infections who currently have few options beyond supportive care. It would not replace antibiotics but would act as an adjunct therapy, potentially reducing mortality and shortening hospital stays. The same platform could be adapted to target other bacterial toxins in the future.